Table 2 Multivariate analysis for different genetic subgroups of total NK-AML patients. All treatment groups (DA, DAC, DAF) were included in the analysis.

End point and variables		P value
*Total AML*(n = 398†)
CR	OR (95% CI)
Age (continuous)	1.05 (1.03–1.072)	0.000000*
WBC (continuous)	1.008 (1.0032–1.013)	1.001*
FLT3-ITD⁺	1.37 (0.77–2.45)	0.27*
NPM1(+)	0.6 (0.35–1.4)	0.067*
IDH2⁺	0.84 (0.4–1.8)	0.66*
4-year OS	HR (95% CI)
Age (continuous)	1.00 (1.00–1.00)	0.014**
WBC (continuous)	1.00393 (1.00148–1.00638)	0.0016**
FLT3-ITD⁺	1.69 (1.24–2.3)	0.0008**
NPM1(+)	0.93 (0.7–1.2)	0.62**
IDH2⁺	0.71 (0.47–1.09)	0.12**
4-year OS censored at allograft	HR (95% CI)
Age (continuous)	1.024 (1.012–1.036)	0.00003**
WBC (continuous)	1.0000 (1.0000–1.000001)	0.00076**
FLT3-ITD⁺	1.54 (1.1–2.16)	0.011**
NPM1(+)	0.91 (0.67–1.26)	0.61**
IDH2⁺	0.6 (0.37–0.93)	0.024**
*Molecular higher risk—only NPM1⁻/FLT3-ITD*⁻ (n = 188)
CR	OR (95% CI)
Age (continuous)	1.05 (1.026–1.073)	0.0000014*
WBC (continuous)	1.006 (1.001–1.01)	0.013*
IDH1⁺	1.55 (0.59–4.12)	0.37*
4-year OS	HR (95% CI)
Age (continuous)	1.026 (1.015–1.04)	0.000008**
WBC (continuous)	1.0035 (1.0014–1.0056)	0.00094**
IDH1⁺	1.65 (0.98–2.78)	0.058**
4-year OS censored at allograft	HR (95% CI)
Age (continuous)	1.023 (1.01–1.04)	0.0002**
WBC (continuous)	1.005 (1.0024–1.007)	0.00012**
IDH1⁺	1.73 (1.02–2.9)	0.04**

CR, overall complete remission rate after all courses of inductions; OS, overall survival; allo OS, overall survival censored at allograft; RFS, cumulative incidence of relapse; SD, standard deviation; HR, hazard ratio; OR, odds ratio; CI, confidence interval. † for whole NK-AML cohort: 3 patients missing IDH2 mutation analysis (2 of IDH2 missing patients were HR NK-AML. 1 was LR); 3 patients missing classification according to NPM1/FLT3-ITD status; ^# computed by log rang test; ^## computed by Chi square or Fisher exact test;* computed by logistic regression analysis;
**Computed by Cox regression analysis.

Search